Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Clinical trial NCT06344715 · UNKNOWN

Trial details

NCT number: NCT06344715
Sponsor: SL VAXiGEN
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start date: 2022-10-17
Primary completion: 2024-10-31
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.